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1  | INTRODUC TION
Pancreatic	 cystic	 lesions	 are	 a	 common,	 often	 incidental	 finding.	
Recent	large	studies	using	magnetic	resonance	cholangiopancrea‐
















patients	with	at	 least	5	years	of	 follow‐up,	 reported	a	pancreatic	
cancer	 risk	 of	 only	 0%‐1.6%	 for	 small	 asymptomatic	 cysts.2,8‐12 
However,	all	these	studies	were	retrospective	and	the	actual,	long‐
term	risk	is	yet	to	be	determined	by	large	and	prospective	studies.
Pending	 definite	 answers,	 the	 European,13	 AGA,14	 ACG,15 and 
international	 Fukuoka16	 guidelines	 recommend	 surveillance	 with	






There	are	 currently	no	 tools	 to	distinguish	 IPMNs	 that	do	not	
warrant	surveillance,	or	that	are	helpful	 in	selecting	a	tailored	and	
optimal	 surveillance	 interval.	Previous	prediction	models	have	 fo‐




at	 lowest	 risk	 of	 developing	worrisome	 features	 or	 high‐risk	 stig‐
mata.	Such	a	stratifying	tool	is	needed	to	prevent	redundant	surveil‐
lance	and	reduce	the	burden	for	patients	and	health	care	systems.
2  | MATERIAL S AND METHODS
2.1 | Study design
We	 included	 pancreatic	 cyst	 surveillance	 data	 from	 prospectively	
maintained	 databases	 of	 three	 academic	 institutions,	 namely	 the	
















Florida).	 From	 these	 databases,	 we	 selected	 patients	 with	 a	 ra‐
diologically	 presumed	 SB‐IPMN	who	 had	 been	 followed‐up	 for	 at	




2.3 | Endpoint and candidate predictors
The	 endpoint	 was	 defined	 as	 the	 development	 of	 one	 or	 more	





index,	 ever	 having	 smoked	 personal	 history	 of	 acute	 pancreatitis,	
personal	history	of	any	type	of	extrapancreatic	malignancy,	 family	




Missing	 data	 were	 imputed	 using	 multiple	 imputation	 by	 chained	
equations	 (MICE)	 based	 on	 the	 posterior	 distributions	 with	 five	
datasets	with	 the	MICE	package	 in	 r	 software.28	We	used	 a	Cox‐
proportional	 logistic	 regression	analysis	 to	develop	a	multivariable	
prediction	model.	A	 linear	 relation	was	 the	 best	 approximation	of	
the	relationship	between	the	endpoint	and	the	continuous	predic‐
tors.	A	backward	stepwise	selection	procedure	was	performed	with	
Akaike's	 Information	Criterion	as	stopping	 rule,	 to	 limit	overfitting	
and	 to	prevent	exclusion	of	 important	predictors.	The	 final	model	





















3.1 | Participants and clinical outcome





























F I G U R E  1  Flow‐chart	of	patient	
selection	and	model	development	process All patients under surveillance for presumed IPMN
Exclusion of patients with at baseline having any of:
1. Jaundice
2. Enhancing solid component
3. Main PD ≥ 10mm














4. Cytology suspicous or
positive for malignancy
High-risk stigmata Worrisome features
5.Cyst size ≥ 3 cm
6.Thickened enhanced cyst wall
7. Main PD 5-9 mm
8. Non-enhancing mural nodule 






















4  |     OVERBEEK Et al




smoked	 (HR	1.40,	 95%	CI	 0.95‐2.04),	 history	 of	 acute	 pancreatitis	
(HR	2.07,	95%	CI	1.21‐3.55),	 and	history	of	 extrapancreatic	malig‐
nancy	(HR	1.34,	95%	CI	0.91‐1.97).	The	hazard	ratios	and	95%	CI	of	










3.4 | Score chart and example
The	Dutch‐American	 Risk	 stratification	 Tool	 (DART‐1)	 visualises	 the	
estimated	3‐year	and	5‐year	risk	of	developing	one	or	more	worrisome	
features	or	high‐risk	stigmata	for	all	possible	predictor	combinations	

















Florida (n = 313)
Patient	characteristics
Age,	mean	(SD),	y 61	(11.0) 65	(11.9) 68	(9.5)
Male	gender 20	(25.3) 197	(40.8) 104	(33.2)
Race
Caucasian 64	(81.0) 295	(61.1) 289	(92.3)
Asian 2	(2.5) 20	(4.1) 3	(1.0)
Black 4	(5.1) 30	(6.2) 16	(5.1)
Other 4	(5.1) 16	(3.3) 1	(0.3)
Unknown 5	(6.3) 122	(25.3) 4	(1.3)




Smoking	ever 27	(34.2) 189	(39.1) 126	(40.3)







Family	history	of	PDAC 10	(12.7) 50	(10.4) 30	(9.6)
Cyst	characteristics
Location	dominant	cyst
Head 52	(65.8) 188	(38.9) 141	(45.0)
Body 22	(27.8) 188	(38.9) 103	(32.9)
Tail 4	(5.1) 106	(21.9) 68	(21.7)






TA B L E  1  Baseline	patient	and	cyst	
characteristics
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optimising	 surveillance	 intervals	 or,	 in	 selected	 cases,	 discontinue	
surveillance.
In	our	 cohort,	multivariable	 analysis	 resulted	 in	 five	predictors	
for	 progression:	 cyst	 size,	 cyst	 multifocality,	 ever	 having	 smoked	
history	 of	 acute	 pancreatitis,	 and	 history	 of	 extrapancreatic	 ma‐
lignancy.	 Cyst	 size	 being	 an	 independent	 predictor	 of	 progression	
comes	as	no	surprise,	given	that	a	size	of	3	centimetres	or	greater	is	
defined	as	a	worrisome	feature27 and therefore incorporated in our 
composite	endpoint.	However,	 it	has	been	shown	in	other	cohorts	
that	initial	cyst	size	is	a	predictor	of	cyst	growth,30‐32 development 
 Total (N = 875)
No development of WF 
or HRS (n = 759)
Development of WF or 
HRS (n = 116)
Centre
Erasmus	UMC 79	(9.0) 65	(8.6) 14	(12.1)





Age,	mean	(SD),	y 66	(11.2) 65	(10.9) 67	(12.8)
Male	gender 321	(36.7) 271	(35.7) 50	(43.1)
Race
Caucasian 648	(74.1) 568	(74.8) 80	(69.0)
Asian 25	(2.9) 22	(2.9) 3	(2.6)
Black 50	(5.7) 41	(5.4) 9	(7.8)
Other 21	(2.3) 18	(2.4) 3	(2.6)
Unknown 131	(15.0) 110	(14.5) 21	(18.1)




Smoking	ever 342	(39.1) 288	(37.9) 54	(46.6)













Head 381	(43.5) 329	(43.3) 52	(44.8)
Body 313	(35.8) 274	(36.1) 39	(33.6)
Tail 178	(20.3) 153	(20.2) 25	(21.6)







TA B L E  2  Patient	and	cyst	
characteristics	separated	on	study	
endpoint
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of	other	worrisome	features,31,33 and malignancy.12 The predictive 
value	of	cyst	multifocality	has	been	described	less	often,	but	is	not	
a	new	finding.	Crippa	et	al	followed	144	patients	with	SB‐IPMN	for	










as	 a	 predictor	 for	 progression	 in	 other	 cohorts.	 In	 the	 previous	
analysis	 of	 a	 subset	 of	 our	 cohort,	 a	 history	 of	 any	 extrapancre‐
atic	malignancy	was	not	an	independent	predictor,	but	a	history	of	
prostate	 cancer	was.	 This	 difference	 is	most	 likely	 attributable	 to	
the	difference	 in	sample	size.	Retrospective	studies	have	reported	
an	 increased	 incidence	of	extrapancreatic	malignancies	 in	patients	
with	IPMN,	but	prospective	studies	were	unable	to	confirm	this.8,42 
Crippa	et	al	did	not	find	an	association	between	extrapancreatic	tu‐






Having	 a	 history	 of	 diabetes	was	 predictive	 in	 the	 univariable	
analysis	 but	 did	 not	 contribute	 significantly	 to	 the	 multivariable	
model	 and	 was	 therefore	 omitted	 from	 DART‐1.	 The	 association	
between	 diabetes	 and	 pancreatic	 cancer	 is	 well‐known,43‐46 but 
the	 association	with	 IPMN	 is	 less	 established.	 Some	 studies	 have	
reported	 an	 increased	 risk	 for	 patients	 with	 diabetes	 to	 develop	
IPMN,1,47	but	 in	another	 large	population‐based	study,	 this	associ‐
ation	 disappeared	 after	 correcting	 for	 age	 and	 body	mass	 index.2 
Morales‐Oyarvide	et	al	showed	that	in	patients	with	resected	IPMN,	


















that	 sample	 size	 is	 retained.49	 DART‐1	 performed	 similarly	 in	 the	
total	cohort	before	validation	(apparent	performance),	the	Columbia	
cohort,	 and	 the	Mayo	 cohort.	 The	 slight	decrease	 in	performance	
within	the	Erasmus	cohort	was	expected	and	is	attributable	to	this	
cohort's	smaller	sample	size.
DART‐1	 shows	 promise,	 but	 should	 be	 interpreted	 with	 some	
caution.	 Foremost,	 prediction	 models	 are	 developed	 to	 augment,	
and	not	replace	clinical	judgment,	and	the	given	risks	are	estimates	
that	 therefore	 hold	 some	 extent	 of	 uncertainty.	 Also,	 it	 is	 crucial	






the	 patient	 population	 in	 the	 primary	 or	 secondary	 care	 setting.	
Additionally,	 we	 observed	 limited	 optimism	 in	 the	 C‐statistic	 and,	
therefore,	a	good	external	performance	is	likely.
The	main	limitation	of	this	prediction	model	is	that	it	uses	a	com‐
posite,	 surrogate	 endpoint.	 Ideally	 it	 would	 predict	 development	
of	malignancy.	However,	given	the	low	cancer	risk	of	SB‐IPMNs,	 it	
would	require	extremely	large	cohorts	to	reach	adequate	numbers	





develop	 into	malignancy.	 Although	 it	 has	 been	 shown	 that	worri‐
some	 features	and	high‐risk	stigmata	accurately	 stratify	 for	malig‐
nancy	 risk,50	 it	 is	 also	 known	 that	 a	 substantial	 number	of	 IPMNs	
with	a	worrisome	feature	do	not	harbor	high‐grade	dysplasia	or	in‐
vasive	carcinoma,21‐23	which	is	supported	by	our	own	results.	IPMNs	





HR 95% CI HR 95% CI
Age 1.01 0.99‐1.03 NA NA
Body	mass	index 1.01 0.96‐1.05 NA NA
Smoking,	ever 1.42 0.98‐2.05 1.40 0.95‐2.04
History	of	diabetes	
mellitus
1.37 0.89‐2.12 NA NA
History	of	acute	
pancreatitis
1.76 1.04‐2.99 2.07 1.21‐3.55
History	of	extrapan‐
creatic malignancy
1.21 0.83‐1.76 1.34 0.91‐1.97
Cyst	multifocality 1.65 1.14‐2.41 1.49 1.01‐2.18
Largest	cyst	diameter,	
per mm
1.12 1.09‐1.15 1.12 1.09‐1.15
Abbreviations:	CI,	confidence	interval;	HR,	hazard	ratio;	NA,	not	ap‐
plicable,	was	not	included	in	the	model	with	the	best	fit.






2012	 international	 Fukuoka	 guidelines,27	 whereas	 these	were	 re‐






of	 these	 parameters.	 Because	 previous	 studies	 have	 shown	 that	








































































































































































































































































No Yes No Yes
History of extrapancreatic malignancy
No Yes No Yes
1 1
(A)
F I G U R E  2  The	Dutch‐American	Risk	stratification	Tool	(DART‐1)	to	identify	side	branch	intraductal	papillary	mucinous	neoplasms	(SB‐
IPMN)	at	low	probability	(%)	of	developing	one	or	more	worrisome	features	or	high‐risk	stigmata	within	3	y	(A)	or	within	5	y	(B)





or	 as	 predictor	 in	 future	 updates.	 Another	 aspect	 that	 could	 not	
be	completely	ruled	out,	 is	 if	our	dataset	contained	a	bias	by	right	
censoring.	However,	 the	predictors	 in	 the	model	did	not	 show	an	
association	with	 follow‐up	 time,	 limiting	 the	 possible	 influence	 of	
this	type	of	bias.





















































































































































































































































































No Yes No Yes
History of extrapancreatic malignancy
No Yes No Yes
(B)
F I G U R E  2  (Continued)
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F I G U R E  3  Web‐based	application	of	the	Dutch‐American	Risk	stratification	Tool	(DART‐1)	with	an	example	patient	with	low	probability	
of	developing	one	or	more	worrisome	features	or	high‐risk	stigmata.	The	application	can	be	found	at	https	://rtools.mayo.edu/DART/
Dutch-American Risk Stratification Tool Calculation About DISCLAIMER
DART-I Score
The three year risk is 2.15 out of 100.
Cyst size (mm):
Is the patient a former or current smoker?
Is the cyst multifocal?
Does the patient have a history of acute pancreatitis?











2 5 8 11 14 17 20 23 26 28
9
3-year Risk






The five year risk is 5.02 out of 100.
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